Archive for the ‘research’ Category

Seroprevalence of Borrelia burgdorferi sensu lato & Anaplasma phagocytophilum Infections in German Horses

https://www.mdpi.com/2076-2615/13/12/1984

Seroprevalence of Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum Infections in German Horses

Received: 15 April 2023 / Revised: 30 May 2023 / Accepted: 10 June 2023 / Published: 14 June 2023

Abstract

There are limited data on Lyme borreliosis (LB), a tick-borne disease caused by the Borrelia burgdorferi sensu lato complex, in horses. Seropositivity is not necessarily associated with clinical disease. Data on seropositivity against Borrelia burgdorferi and Anaplasma phagocytophilum in German horses are sparse. Therefore, serum samples from horses (n = 123) suspected of having Lyme borreliosis and clinically healthy horses (n = 113) from the same stables were tested for specific antibodies against Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum. The samples were screened for antibodies against Borrelia burgdorferi (ELISA and an IgG line immunoblot assay). Furthermore, the samples were examined for antibodies against B. burgdorferi and Anaplasma phagocytophilum with a validated rapid in-house test (SNAP® 4Dx Plus® ELISA).
The clinical signs of suspect horses included lameness (n = 36), poor performance (n = 19), and apathy (n = 12).
Twenty-three percent (n = 26) of suspect horses and 17% (n = 18) of clinically healthy horses were seropositive for having a Borrelia burgdorferi sensu lato infection (p = 0.371), showing that the detection of specific antibodies against B. burgdorferi alone is not sufficient for a diagnosis of equine LB. Anaplasma phagocytophilum seropositivity and seropositivity against both pathogens was 20%/6% in suspect horses and 16%/2% in the clinically healthy population, showing only minor differences (p = 0.108). Unspecific testing for antibodies against B. burgdorferi without clinical suspicion of Lyme borreliosis is not recommended since the clinical relevance of seropositivity against Borrelia burgdorferi sensu lato remains to be elucidated.
________________

Autoimmune Inflammatory Reactions in Terminally Differentiated Tissues & Inability to Work Following COVID Shots – A Relevant Aspect For Future Boosters

https://www.researchgate.net/publication/373925710_Autoimmune_inflammatory_reactions_triggered_by_the_COVID19_genetic_vaccines_

Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues

Abstract

As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group.
Numerous studies report the onset of autoimmune reactions following COVID-19 vaccination [47, 59-76]. The histopathological data provide indisputable evidence that demonstrates that the genetic vaccines exhimbit an off-target distribution, causing the synthesis of the spike protein and thus triggering autoimmune inflammatory reactions, even in tissues which are terminally differentiated and subject to symptomatic damage [38-40, 42].
______________________
The conclusions are inescapable, mRNA vaccines will cause autoimmunity in all applications. The human body is simply too good at recognizing foreign proteins that populate at the cell surface synthesized from mRNA on ribosomes in the Golgi complex. ~ Dr. Peter McCullough

https://pubmed.ncbi.nlm.nih.gov/37562083/

Inability to work following COVID-19 vaccination-a relevant aspect for future booster vaccinations

PMID: 37562083

DOI: 10.1016/j.puhe.2023.07.008

Abstract

Objectives: COVID-19 vaccination is a key prevention strategy to reduce the spread and severity of SARS-CoV-2 infections. However, vaccine-related inability to work among healthcare workers (HCWs) could overstrain healthcare systems.

Study design: The study presented was conducted as part of the prospective CoVacSer cohort study.

Methods: This study examined sick leave and intake of pro re nata medication after the first, second, and third COVID-19 vaccination in HCWs. Data were collected by using an electronic questionnaire.

Results: Among 1704 HCWs enrolled, 595 (34.9%) HCWs were on sick leave following at least one COVID-19 vaccination, leading to a total number of 1550 sick days. Both the absolute sick days and the rate of HCWs on sick leave significantly increased with each subsequent vaccination. Comparing BNT162b2mRNA and mRNA-1273, the difference in sick leave was not significant after the second dose, but mRNA-1273 induced a significantly longer and more frequent sick leave after the third.

Conclusion: In the light of further COVID-19 infection waves and booster vaccinations, there is a risk of additional staff shortages due to post vaccination inability to work, which could negatively impact the already strained healthcare system and jeopardize patient care. These findings will aid further vaccination campaigns to minimize the impact of staff absences on the healthcare system.

For more:

See Twitter link to enlarge graph

Study: Oral NAD+ & NMN Increases Intracellular NAD+ & Lowers Triglycerides

https://www.townsendletter.com/e-letter-17-nad_plus-supplementation-and-cellular-energy/

Case Study: Oral Supplementation with the NAD+ Precursor Nicotinamide Mononucleotide (NMN)—Effects on Intracellular NAD+ and Triglycerides.

Alan Miller, ND

Abstract

NAD+ is a coenzyme that is essential in numerous metabolic reactions, the most important involving energy production. In the cellular respiration process, NAD+ is required for the production of ATP (adenosine triphosphate), the primary energy currency of cells. NAD+ transfers electrons from molecules including glucose during glycolysis and the citric acid cycle. These electrons are then transferred to the electron transfer chain, where NAD+ acts as an essential mediator in energy production, ensuring the efficient functioning of cells. NAD+ is also critically involved in DNA repair and healthy aging sirtuin enzymes.

Nicotinamide Mononucleotide (NMN) is the most direct biochemical precursor to NAD+ and thus supplementation of this molecule is an efficient method of increasing intracellular NAD+, which can improve cellular energetics and markers of aging. NMN may also lower triglycerides. In a study of intravenous dosing of 300 mg NMN in 10 healthy individuals, researchers discovered a significant reduction in serum triglycerides.

One concern with NMN is that when taken in an oral dose this molecule might be damaged or otherwise metabolized by stomach acid, pancreatic enzymes, or first pass hepatic enzymes. In other studies, we have shown that a liposomal powder preparation can protect other molecules, such as glutathione, from this type of degradation and significantly increase blood levels of the whole molecule.

We performed a small case study in which individuals were given 1000 mg of an oral liposomal NMN preparation (powder in a capsule) once after a baseline blood test. Serial triglyceride tests were performed hourly for five hours. Participants had an average of 15% decrease in triglycerides at hour five, compared to baseline. Another group was tested at baseline for intracellular NAD+ (Jinfinity Labs), then was given 1000 mg of a liposomal powder NMN daily for 15 days. An intracellular NAD+ test was then performed after 15 days. NAD+ levels increased 100 percent over this period.

This is the first case series that has demonstrated a rapid triglyceride-lowering effect of oral liposomal NMN (over 5 hours), along with a 100-percent increase in intracellular NAD+ over a 15-day period.

(See link for full article)

For more:

Correlation Between COVID-19 Severity and Previous Exposure to Borrelia spp.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509370/

Abstract

Predictors for the risk of severe COVID-19 are crucial for patient care and control of the disease. Other infectious diseases as potential comorbidities in SARS-CoV-2 infection are still poorly understood. Here we identify association between the course of COVID-19 and Lyme disease (borreliosis), caused by Borrelia burgdorferi transmitted to humans by ticks. Exposure to Borrelia was identified by multi-antigenic (19 antigens) serological testing of patients:

  1. severe COVID-19 (hospitalized)
  2. asymptomatic to mild COVID-19 (home treated or not aware of being infected)
  3. infected with SARS-CoV-2

Increased levels of Borrelia-specific IgGs strongly correlated with COVID-19 severity and risk of hospitalization. This suggests that a history of tick bites and related infections may contribute to the risks in COVID-19. Though mechanisms of this link is not clear yet, screening for antibodies targeting Borrelia may help accurately assess the odds of hospitalization for SARS-CoV-2 infected patients, supporting efforts for efficient control of COVID-19.

_________________

**Comment**

Nothing shocking or new here.  Those who infected with Lyme/MSIDS are immunocompromised and are sitting ducks for about any disease that comes down the pike.  Don’t let this make you fearful, because stress is after-all, just as deadly.

Know you are compromised and then take actionable steps to mitigate your risk.

Make sure you are in good, effective treatment if you have symptoms, strengthen the immune system, avoid sugar and anything else that lowers the immune system and work with your doctor on supplements/antimicrobials, etc. that will help you fight off viruses and other opportunistic infections. This has always been the advice of Lyme literate doctors.  Nothing has changed.  Keep on, keeping on.

For more:

As Lyme Disease Expands Its Reach, New Research Offers Hope (But Not Really)

https://jamanetwork.com/journals/jama/fullarticle/2809395

Medical News & Perspectives
Climate Change and Health
September 6, 2023

As Lyme Disease Expands Its Reach, New Research Offers Hope

JAMA. Published online September 6, 2023. doi:10.1001/jama.2023.15358

Public health warnings about vector-borne diseases in the US are heating up. In a May editorial, scientists from the Centers for Disease Control and Prevention (CDC) made a plea for a vaccine against West Nile virus, which is spread by mosquitoes and has no treatment. By midsummer, the CDC reported that as many as 450 000 people in the US may have a meat allergy from the bite of the lone star tick, while other CDC scientists warned that mosquitoes are becoming resistant to the insecticides used in abatement efforts. Mosquitoes struck in August, when public health officials reported 11 cases of locally acquired dengue fever in Florida and Maryland’s first known case of locally acquired malaria in more than 40 years.

Meanwhile, the most common vector-borne disease in the US, Lyme disease, is on the rise.

“Lyme disease is definitely increasing in the US as the environmental niche of the deer tick and deer populations expand,” John N. Aucott, MD, director of the Lyme Disease Research Center at the Johns Hopkins University School of Medicine, told JAMA in an interview. The incidence of Lyme disease in the US nearly doubled from 1991 to 2018, from 3.74 cases to 7.21 cases per 100 000 people, based on confirmed cases reported to the CDC. But the true numbers are believed to be much higher.

According to the nonprofit organization Fair Health, US private insurance claims with a Lyme disease diagnosis increased 357% in rural areas and 65% in urban areas from 2007 to 2021. Using insurance claims, the CDC estimates that as many as 476 000 people in the US are diagnosed with and treated for Lyme disease each year.

“In the last 20 years, the numbers of Lyme disease have really exploded,” said Linden Hu, MD, director of the Lyme Disease Initiative at Tufts University School of Medicine. “We’ve seen people get Lyme disease just from stopping at a rest stop in Massachusetts. So the number of people at risk is greater than it was before.”

(See link for article)

___________________

**Comment**

There is very little hope within this article.

Summary:

  • Climate change clap trap continues to be regurgitated and blamed for what we are experiencing, despite ticks being ecoadaptive and the last species to die on planet earth.
  • PTLDS is emphasized only due to the fact there is “no known treatment,” so vaccines can be pushed.
  • The article gives false hope by stating the NIH has announced $3.2 Million in funding to support research on PTLDS; however, what isn’t mentioned is this money will do NOTHING to help patients.  It will simply line the pockets of biased, bought out researchers who will continue with the accepted, politically motivated narrative.
  • The falsely low number of 10-20% who continue with lingering symptoms is regurgitated when the number is upwards of 40-60%.
  • Hu managed to mention the fact that persistent infection after treatment is one hypothesis for PTLDS along with immune responses and autoantibodies.
  • And Aucott also managed to mention that due to his magnetic imaging studies which showed there is underlying biology to explain patients’ symptoms, it is not psychosomatic.
  • Of course nothing would be complete without a huge section on vaccines. (This is getting very old)  It’s also a good time to reflect upon the conflict of interest disclosures:

Dr Hu reported having financial relationships with Moderna and Tarsus. Dr Fikrig reported that he is funded by the NIH, the Cohen Foundation, and the Howard Hughes Medical Institute’s Emerging Pathogens Initiative. Dr Wormser reported receiving research grants from Biopeptides Corp and Pfizer Inc; being an expert witness in malpractice cases involving Lyme disease; and serving as an unpaid board member of the nonprofit American Lyme Disease Foundation.

  • The article made Lymerix seem like the answer to all of life’s ills when in fact it was yanked off the market for causing Lyme-like symptoms.  To those who tout the narrative, Lymerix, like all other vaccines, is “safe and effective.”  (This too is getting extremely old)
  • But, there’s a new vaccine to save humanity in the pipeline! Yay! This “antitick vaccine” encodes a cocktail of 19 proteins in tick saliva.  What could possibly go wrong?! 
  • Hu is developing lotinaner, used in the veterinary world, of which the FDA has given an alert about potential neurological adverse events, muscle tremors, ataxia, and seizures.
  • Aucott mentioned that the “classic” bullseye rash is a myth as only 20-30% have a bullseye pattern, and that many have no rash at all.  So, sorry all you suckers that didn’t fit in the box, were told you had a spider bite, and sent home empty-handed to suffer in silence.  Oops!
  • Aucott mentons testing problems: test results take 4-8 weeks before an antibody test is definitive, and following treatment – serology results will remain positive.
  • Wormser of course dissuades from prophylactic treatment unless a confirmed deer tick has been attached for 36 hours – the notion of which has been proven to be false.  He’s more worried about staph than people getting Lyme/MSIDS and living a nightmare. Plus, there are other antimicrobials in the toolbox that can be used that wouldn’t promote resistance.
  • Alpha Gal meat allergy is all the rage now because of The Great Reset and the desire to eliminate meat and get us all eating bugs.  A report has even predicted that the next ‘pandemic’ will conveniently come from meat.  It’s a win, win for ‘the powers that be.’
  • The article falsely blames climate change and the Lone Star tick when other ticks are involved, or even NO ticks at all. They have only discovered that tick saliva contains trace quantities of the sugar alpha-gal a known human irritant that many believe induces an allergic response.
  • But alpha-gal is also is used in the manufacture of foods, personal care products, medical devices and drugs — including vaccines.  Source
  • The questions begging to be asked are: why are they putting this known human irritant in things that humans ingest?  And why the sole emphasis on ticks when it’s in plenty of other things including vaccines, and is only believed to be caused by ticks?
It should come at no surprise whatsoever that the media is suddenly pushing a fear narrative over a meat allergy.
Again – right on time.